Oligonucleotide therapy |
| |
Authors: | Stanley T Crooke |
| |
Institution: | Isis Pharmaceuticals, Carlsbad, California 92008. |
| |
Abstract: | Rapid progress in oligonucleotide therapeutics has continued over the past year as major programs established in the past four years have grown and begun to be productive. Important advances were reported in the medicinal chemistry of oligonucleotides and in understanding their pharmacodynamic properties. Significant progress was made in understanding the pharmacokinetic and toxicologic properties of first generation analogs, particularly phosphorothioates and one oligonucleotide, ISIS 2105, entered clinical trials. Additionally, combinatorial approaches designed to identify oligonucleotides that may bind to a variety of targets were reported. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|